PHOTO
- Department of Health – Abu Dhabi commends initiative that aims to enhance efforts of public and private sectors to utilize the emirate’s advanced infrastructure in enriching its healthcare medical research
- Launched by G42 Healthcare, regional contract research organization (CRO) to support global innovation for life-changing treatments
- Real-world data (RWD) and Artificial Intelligence (AI) tools to support high standards of scientific and ethical research
Abu Dhabi: Reinforcing the growing significance of the UAE in global healthcare research, Insights Research Organization and Solutions (IROS) – the first-of-its-kind Contract Research Organization (CRO) in the UAE— has been launched, specializing in healthcare research and solutions that will span across all therapeutic areas.
Based in Abu Dhabi, IROS is born out of G42 Healthcare – a leading health-tech company on a mission to offer world-class healthcare in the UAE and beyond — and follows in its vision. IROS will harness the power of real-world data (RWD) and Artificial Intelligence (AI) to support internationally leading standards of scientific and ethical research, conduct clinical trials and reporting, alongside key solutions, and insights to expand and ensure access to and innovation of life-changing treatments.
The IROS debut marks a significant milestone in UAE’s growing prominence in the global healthcare research and development space, spurred on by the success of the country’s Phase III clinical trials for the development and testing of an inactivated COVID-19 vaccine.
The focus of IROS is to provide intelligent and high-quality solutions to help develop new drugs and medications by leveraging state-of-the-art research capabilities and groundbreaking technologies. This will invigorate the generation of revolutionary treatments to address pressing healthcare challenges of the present and the future.
Dr. Walid Zaher, CEO of IROS and Chief Research Officer at G42 Healthcare, said, “With the increasing incidence of chronic diseases, cancer, and hematological disorders that require life-saving drugs, the MENA region needs a sustainable and robust clinical research infrastructure. The UAE has an immense capacity for research and the substrate to develop a strong regulatory framework, which makes it an ideal location to build a CRO to service the needs of the region. With its surrounding population size and diversity in genetic profile and lifestyle, IROS – driven by the latest technologies, AI capabilities, and algorithms—has the perfect landscape to foster research and testing, leading to innovative new drugs and therapies.”
The launch of IROS is supported by the progressive UAE leadership that recognizes the need of such entities to address healthcare challenges and provide a supportive ecosystem for
world-class research facilities and clinical research trials in line with the highest standards and global practices.
The new organization will enhance Abu Dhabi’s capabilities and spotlight its contributions in developing medical solutions and leading robust research at a global level. The Department of Health, Abu Dhabi commended this initiative that aims to enrich and unify efforts of public and private sectors to utilize the emirate’s advanced infrastructure in enhancing its healthcare medical research capabilities.
Dr. Asmaa Al Mannai, Executive Director, Research and Innovation, Department of Health, Abu Dhabi, said, “Abu Dhabi continues its leading position in health research and clinical trials and enhances its role as part of the global efforts to push forward the healthcare sector and achieve a better life for societies across the world. Today, we are witnessing in Abu Dhabi the launch of many initiatives that stress the importance of unifying efforts of public and private sectors and achieve shared goals that rely on utilizing the emirate’s capabilities to offer preventive and treatment innovations that improve the health and wellbeing of people around the globe.”
She added: “IROS will help enhance Abu Dhabi’s position as an incubator for innovation and scientific research, especially in the health sector that continues to evolve so that the emirate becomes one of the leading global destinations for those looking to work in the sector, visit for treatment purposes, or invest in healthcare.”
The population diversity in the UAE and the GCC offer a unique advantage in clinical trials that can comprehensively demonstrate the safety and efficacy of new drugs, vaccines, and other therapeutic products across a diversified range of individuals.
IROS provides comprehensive, tailored, highly skilled and knowledgeable project management and real-world evidence-based solutions. This will help create and deliver a detailed roadmap of the research process, from design to completion. The IROS team will integrate meticulous quality, thorough trial navigation, and dynamic outcomes, ensuring streamlined clinical trials from planning through to market.
IROS offers a broad range of customized solutions that span from integrating and optimizing a wide range of data and analytics to fulfilling all trial needs to medical writing and publication support. Security and safety are top priority, utilizing advanced computing, deft personnel, innovative technologies, and efficient governance to protect, progress, and advance each clinical trial.
IROS will be a game-changer in the coming generation of clinical trials, drug discovery, and population validation, as well as an important player in the global aim for augmented representation of diversity and access to much needed therapeutics.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
